Developers of Russia’s Sputnik V coronavirus vaccine have said it is 95 percent effective against the virus.
Russia’s health ministry, the state-run Gamaleya research center and the Russian Direct Investment Fund (RDIF) in a statement said the calculations were based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose).
Read Also: Breaking: Russia Approves ‘World’s First’ Coronavirus Vaccine
This is based on the analysis of data on volunteers who received both the first and second doses of the Sputnik V vaccine or placebo at the second control point (39 confirmed cases as of November 23, 2020) in accordance with the clinical trial protocol.
Preliminary data from volunteers obtained 42 days after the first dose (corresponds with 21 days after the second dose) indicates an efficacy of the vaccine above 95%.
The interim research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals.
Following the completion of Phase III clinical trials of the Sputnik V vaccine, Gamaleya Center will provide access to the full clinical trial report.
Currently, 40,000 volunteers are taking part in the Phase III double-blind, randomized, placebo-controlled clinical post-registration study of the Sputnik V vaccine in Russia.
More than 22,000 volunteers were vaccinated with the first dose and over 19,000 volunteers with the first and second doses.
There are now at least three COVID-19 vaccines that have been developed that have showed high rate of effectiveness against the virus.
Read Also: COVID-19: Pfizer-BioNTech Says Vaccine Now 95% Effective
Biotech companies, Pfizer and BioNTech on Wednesday, November 17 revealed that a completed study of their experimental COVID-19 vaccine showed it is 95 percent effective against the virus.
Read Also: Breaking: COVID-19 Vaccine 94.5% Effective, Says US Biotech Firm, Moderna
Also, a US biotech firm, Moderna Inc also announced this month that its COVID-19 experimental vaccine was 94.5% effective, in a preliminary study.
The companies are now seeking emergency use authorization from US Food and Drug Administration.
